Replies to post #297347 on Amarin Corp Plc (AMRN)

[zmanindc]

Have they not already admitted to the intent to infringe based on their investor presentations? Didn’t Hikma guide $700 million in sales which is more than the current marine and reduce-it sales.

[ilovetech]

HDK, Trig> 135 SOC guidelines includes >500 Marine Pop. Regardless of what's on the Generics label, Generics have to know, as do Doctors, both risk factors should be treated, and to ignore CVD in favor of the other is malpractice. That's the whole enchalada right there. It's in plane sight. I don't know about the Opotex case, but there's no grey area here. If the court agrees that a strict Marine Label can avoid infringement, then the court is COMPLICIT to incentivising Generics to cause HARM to society, when in fact it's known that Marine patients are at high RISK for CVD, and should be treated for both risk factors, not one in isolation.

ILT

[Biobillionair]

Thank you!
BB

[Albino2]

I have heard it stated that Amarin can't sue doctors and insurance companies because they just can't afford to risk their reputation etc. But as a one drug company with nothing to lose in the US why not? Why not sue everyone every time? BP may even back the effort since they lose out all the time and have legitimate reasons why they can't afford the reputation risk. But Amarin literally has nothing to lose by suing every one who prescribes off label or pharmacies that switch off label.

[ziploc_1]

Everyone involved, including Doctors,lawyers, pharmacists, patients, and judges are well aware that the Generics' strategy is to, by virtue of their skinny Marine label, infringe on the Reduce-It label by having Vascepa prescribed for patients, who are meant to utilize Vascepa...not for triglycerides over 500mgm/dcl.,but for the more profitable Reduce-It CVD indications...I don't think anyone can argue with a straight face that this is not the Generics' strategy to infringe on Amarin's patents